Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, +15

New England Journal of Medicine

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba, +249

The Lancet

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu, +14

Journal of Clinical Oncology

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu, +14

The Lancet Oncology

OncologyCancer ManagementMaintenance TherapyCancer TreatmentMedicine +3

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Nick Thatcher, Fred R. Hirsch, Alexander Luft, +17

The Lancet Oncology

First-line TherapyMedicinePathologyImmune Checkpoint InhibitorCisplatin Versus Gemcitabine +5

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

Glenwood Goss, Andrew Arnold, Frances A. Shepherd, +17

Journal of Clinical Oncology

Advanced NsclcMedicinePhase IiiPharmacologyClinical Trials +10

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

Mark A. Socinski, Egbert F. Smit, Paul Lorigan, +15

Journal of Clinical Oncology

International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1

Giorgio V. Scagliotti, Ihor Vynnychenko, Keunchil Park, +15

Journal of Clinical Oncology

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

Luis Paz‐Ares, J. Mezger, Tudor–Eliade Ciuleanu, +22

The Lancet Oncology

First-line TherapyMedicinePathologyImmune Checkpoint InhibitorCancer Treatment +4

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

Joachim von Pawel, Jimmie H. Harvey, David R. Spigel, +7

Clinical Lung Cancer

Phase Ii TrialMedicineImmunologyCell DeathImmune Checkpoint Inhibitor +5